Karen Langhauser

Karen Langhauser

Editor-in-Chief
Cell & Gene Therapy Review

Karen currently serves as editor in chief for both Tablets & Capsules and CompareNetwork's newest launch, Cell & Gene Therapy Review.

As an award-winning journalist with 20+ years experience in b2b media, Karen passionately believes that b2b content does not have to boring. She began her career writing for Food Manufacturing magazine before making the leap to pharmaceuticals in 2013. During her tenure at Pharma Manufacturing, Karen prided herself in keeping the brand's editorial look, tone and content fresh and accessible. Under her guidance, Pharma Manufacturing won 65 editorial and design awards, including being named ASBPE's Magazine of the Year in 2021. Karen graduated with honors from Bucknell University, where she majored in English and played Division 1 softball for the Bison. Happily living in NJ's famed Asbury Park, Karen is a retired Garden State Rollergirl, known to the roller derby community as the 'Predator-in-Chief.'
Contact Karen

Articles by Karen Langhauser

  • FDA approvals for cell and gene therapies stay on track

    Monday, November 25, 2024
    The industry stays on track with FDA approvals for cell and gene therapies

  • Switzerland: A rising hub for cell and gene therapies

    Friday, December 13, 2024
    With a well-established infrastructure that spans the entire pharma value chain from APIs to manufacturing, Switzerland is uniquely positioned to become a specialized hub for the most promising area of advanced medicine — cell and gene therapies.

  • The biggest challenges in cell and gene therapy

    Monday, February 03, 2025
    To benchmark the sector’s progress in the inaugural issue of Cell & Gene Therapy Review, we asked thought leaders a single question: What is the biggest challenge facing the CGT sector in 2025?

  • 2025 cell and gene challenges: Investment, technology and innovation

    Monday, February 03, 2025
    To benchmark the sector’s progress in the inaugural issue of Cell & Gene Therapy Review, we asked thought leaders a single question: What is the biggest challenge facing the CGT sector in 2025?

  • 2025 cell and gene challenges: Thoughts from our editorial board

    Monday, February 03, 2025
    To benchmark the sector’s progress in the inaugural issue of Cell & Gene Therapy Review, we asked thought leaders a single question: What is the biggest challenge facing the CGT sector in 2025?

  • 2025 cell and gene challenges: Scalability, supply chain and manufacturing

    Monday, February 03, 2025
    To benchmark the sector’s progress in the inaugural issue of Cell & Gene Therapy Review, we asked thought leaders a single question: What is the biggest challenge facing the CGT sector in 2025?

  • Within reach: Bringing cell and gene therapies to under-resourced regions

    Tuesday, February 18, 2025
    As multiple stakeholders come at the problem from different angles, sustainable global access pathways are beginning to align. From process efficiencies aimed at reining in costs to innovative manufacturing and go-to-market models, cell and gene therapies are charting a course towards future milestones.

  • Written in the CARs

    Tuesday, February 25, 2025
    To quote Astronomers Without Borders, “Boundaries vanish when we look skyward.” In a perfect world, this same philosophy would guide global access to cell and gene therapies.

  • Above the noise: CGT developers focus on access to better treatments amid immunology boom

    Monday, May 05, 2025
    The urgency of unmet need has not evaded the CGT sector, which has executed a ‘strategic pivot’ into autoimmune disease. Developers with B-cell targeting therapies originally designed to detect and kill cancer cells have recognized the potential of these assets to clear the autoreactive B cells that are the problematic hallmark of many autoimmune diseases.

  • Shooting for immune

    Tuesday, May 13, 2025
    While it is still early days for CGTs in autoimmune disease, the field is actively pushing its own limits, working to translate scientific excitement into better, more accessible products. Not only could this lift cell therapies to new heights, but it could redefine them entirely.